DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

MRK·Merck & Co., Inc.

$.
-. (-.%)
After Hours
High
$125.70
Open
$125.12
Market Cap
306.84B
52W High
$130.29
Low
$122.90
P. Close
$123.54
P/E
34.34
52W Low
$76.66
Fwd P/E
12.82
DailyIQ Est.
$136.54
Technical Score (1D)
73
BUY
News Sentiment
68
BULLISH
Merck shares slipped 1.22% to $123.54, lagging broader indices, reflecting short‑term market volatility. The decline comes ahead of the company’s earnings announcement on Aug 4 2026, which could clarify its financial trajectory. Consensus estimates project a quarterly EPS of $2.15 and revenue of $16.3 B, slightly up year‑over‑year. Separately, the FDA approved a KEYTRUDA® plus Padcev® combination for neoadjuvant and adjuvant therapy in muscle‑invasive bladder cancer, expanding Merck’s oncology portfolio. This approval is based on Phase 3 KEYNOTE trials and offers a new treatment pathway for patients who cannot receive cisplatin, potentially boosting the company’s revenue prospects in the uro‑oncology market. The combination’s first‑in‑class status could alter competitive dynamics and influence future guidance on oncology sales. Berenberg raised its price target to $127 from $125 while maintaining a hold rating, signaling a modest bullish outlook amid steady earnings expectations. Traders should monitor the upcoming earnings release for any guidance changes that could shift market expectations. Additionally, keep an eye on regulatory developments and the competitive landscape in bladder cancer to gauge the long‑term impact on Merck’s oncology segment.
Earnings Summary
Merck & Co., Inc. is a global healthcare leader focused on discovering, developing, and delivering innovative medicines and vaccines, with a core portfolio spanning oncology, vaccines, and diabetes, and a significant animal health segment. The company operates within the broader drug manufacturers sector, competing in a highly regulated and research-intensive environment. In the most recent quarter, Merck reported earnings per share of $2.04 against an estimate of $2.03 and revenue of $16.4 billion versus an estimate of $16.35 billion, marking a modest revenue uptick and a slight EPS beat after a strong streak of quarterly earnings. Compared to the prior two quarters—Q2 2025 (EPS $2.13, revenue $15.8 billion) and Q3 2025 (EPS $2.58, revenue $17.3 billion)—the company experienced a sharp decline in EPS to $2.04 and a 5 % revenue drop, reflecting a reversal of the upward momentum seen in the second half of 2025. Over the past six quarters, Merck has consistently outperformed analyst expectations, beating EPS estimates in five of six reports and revenue estimates in both quarters with available guidance, underscoring a pattern of resilient top‑line growth even as profitability fluctuates. Recent analyst coverage highlights a surge in Zacks focus, upgraded price targets from Morgan Stanley and Wells Fargo, and a new access agreement for its HIV therapy IDVYNSO, all of which signal heightened investor scrutiny and potential catalysts tied to pipeline and pricing developments. Investors should watch for the Q2 2026 earnings release, particularly the guidance on revenue and margin trends, the rollout of IDVYNSO pricing, early sales data for the newly approved KEYTRUDA indications, and any regulatory updates that could confirm or challenge the company’s growth narrative.

EPS

EstBeatMiss
$-1.86$-0.60$0.65$1.90$3.16Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-0.26 - -
Q1'26$2.09$-1.28-161.2%
Q4'25$2.03$2.04+0.5%
Q3'25$2.35$2.58+9.9%
Q2'25$2.03$2.13+5.0%
Q1'25$2.14$2.22+4.0%

Revenue

EstBeatMiss
$15.3B$15.8B$16.4B$17.0B$17.5BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$16.5B - -
Q1'26$16.2B$16.3B+0.7%
Q4'25$16.3B$16.4B+0.3%
Q3'25 - $17.3B -
Q2'25 - $15.8B -
Q1'25 - $15.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MRK Stock Snapshot

MRK is currently trading at $123.97, giving Merck & Co., Inc. a market cap of 306.84B and a P/E ratio of 34.3. Today's range spans $122.90–$125.70, with shares opening at $125.12 and moving up $0.43 (0.3%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 68/100.

Over the past year MRK has traded between $76.66 and $130.29 - the current price is +61.7% off the 52-week low and -4.9% from the high. 38 analysts cover the stock with a Buy consensus and a mean 12-month target of $132.07 (range $100.00–$155.00), implying upside of +6.5%.

What MRK has right now - BUY signal, 73/100 technical score, bullish sentiment at 68/100, price $123.97 (near 52-week highs) - is the profile that shows up in screens looking for Healthcare growth stories with technical confirmation. (P/E: 34.3) At 306.84B in capitalization, the risk/reward of a setup like this is often better than in mega-cap peers where the same signal translates to a smaller percentage move. Range: $76.66–$130.29.

What makes MRK's BUY setup (73/100) particularly actionable at 306.84B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $123.97 (near 52-week highs in $76.66–$130.29), with sentiment running bullish at 68/100, the setup rewards conviction-sized positioning more than it does speculative small bets.